Status:

COMPLETED

Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery

Lead Sponsor:

Shenzhen People's Hospital

Conditions:

Osteopenia

Spine Fusion

Eligibility:

All Genders

40-85 years

Phase:

NA

Brief Summary

Degenerative lumbar spinal diseases have become a common health problem and the most frequent indication for spinal surgery in elderly individuals. It mainly contain lumbar spinal stenosis and spondyl...

Detailed Description

However, It was still unknown for denosumab effect on osteopenia patients after lumbar fusion. Bone mineral density(BMD), bone turnover marker, lumbar functional status Roland-Morris Disability Functi...

Eligibility Criteria

Inclusion

  • Participants aged 40 to 85 years
  • who diagnosed with lumbar spinal stenosis or lumbar spondylolisthesis
  • osteopenia with BMD T score between -1.0 and -2.5 via dual-energy X-ray
  • low back pain or leg numbness or weakness
  • MRI demonstrated signs of nerve compression

Exclusion

  • cauda equina syndrome
  • progressive neurologic deficit
  • history of cancer
  • scoliosis greater than 15°
  • back open surgery history
  • have contraindications for surgery
  • who had anti-osteoporosis medication within 6 weeks

Key Trial Info

Start Date :

January 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 10 2023

Estimated Enrollment :

76 Patients enrolled

Trial Details

Trial ID

NCT05415657

Start Date

January 12 2020

End Date

January 10 2023

Last Update

January 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ShenzhenPH

Shenzhen, Guangdong, China, 518000